• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inmed Pharmaceuticals Inc (NQ: INM )

    0.2250 -0.0180 (-7.41%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Inmed Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 7 Next >
    CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Fiscal 2024 Financial Results, Provides Business Update
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CBDNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth
    Via Investor Brand Network
    Topics Cannabis
    Exposures Cannabis
    InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy
    Via Investor Brand Network
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901
    Via Investor Brand Network
    CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment
    Via Investor Brand Network
    BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD
    Via Investor Brand Network
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
    Via CannabisNewsWire
    Topics Cannabis
    Exposures Cannabis
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
    Via Investor Brand Network
    Topics Cannabis
    Exposures Cannabis
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
    Via Investor Brand Network
    InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
    Via Investor Brand Network
    InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
    Via CannabisNewsWire
    BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment
    Via Investor Brand Network
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases
    Via Investor Brand Network
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference
    Via Investor Brand Network
    CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results, Business Update
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board
    Via Investor Brand Network
    CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD
    Via Investor Brand Network
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies
    Via Investor Brand Network
    TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension
    Via Investor Brand Network
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update
    Via Investor Brand Network
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer
    Via Investor Brand Network
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat
    Via Investor Brand Network
    CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones
    Via Investor Brand Network
    CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones
    Via CannabisNewsWire
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Approves Election of Directors During 2023 Annual General Meeting
    Via Investor Brand Network
    InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular Degeneration
    Via Investor Brand Network
    TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q1 Fiscal 2024 Financial Results, Provides Business Update
    Via Investor Brand Network
    Topics Supply Chain
    Exposures Supply Chain
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI
    Via Investor Brand Network
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings
    Via Investor Brand Network
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.